On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...
The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...
In a report released yesterday, Joon Lee from Truist Financial maintained a Buy rating on Argenx Se (ARGX – Research Report), with a ...
Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...
Running back Cam Akers is returning to Minnesota. The Houston Texans have agreed to trade Akers to the Vikings, the Vikings announced Tuesday night. Minnesota will also get a conditional 2026 ...
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
Investor's Business Daily on MSN21h
Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside'Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...
AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback